epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLC10.17749/2077-8333/epi.par.con.2024.186epilepsia-1102Research ArticleORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИCost of epilepsy in the Russian FederationСтоимость заболевания эпилепсией в Российской Федерацииhttps://orcid.org/0000-0001-6641-8803РомановА. С.RomanovA. S.

Романов Антон Сергеевич

пр-т Ленина, д. 40, Барнаул 656038

Scopus Author ID: 58532713600

Anton S. Romanov 

40 Lenin Ave., Barnaul 656038

Scopus Author ID: 58532713600

anton.joerom@gmail.comhttps://orcid.org/0000-0002-3143-8748ШараховаЕ. Ф.SharakhovaE. F.

Шарахова Елена Филипповна, д.фарм.н., проф.

пр-т Ленина, д. 40, Барнаул 656038

Elena F. Sharakhova, Dr. Sci. Pharm., Prof. 

40 Lenin Ave., Barnaul 656038

 

https://orcid.org/0000-0003-3635-5850ШоваН. И.ShovaN. I.

Шова Наталья Игоревна, к.м.н.

ул. Бехтерева, д. 3, Санкт-Петербург 192019

Scopus Author ID: 57215893698. WoS Researcher ID: AAI-3755-2020

Natalia I. Shova, PhD 

3 Bekhterev Str., Saint Petersburg 192019

Scopus Author ID: 57215893698. WoS Researcher ID: AAI-3755-2020

https://orcid.org/0000-0002-7700-2704МихайловВ. А.MikhailovV. A.

Михайлов Владимир Алексеевич, д.м.н., проф.

ул. Бехтерева, д. 3, Санкт-Петербург 192019

ул. Аккуратова, д. 2, Санкт-Петербург 197341

WoS Researcher ID: B-3272-2017

Vladimir A. Mikhailov, Dr. Sci. Med., Prof. 

3 Bekhterev Str., Saint Petersburg 192019

2 Akkuratov Str., Saint Petersburg 197341

WoS Researcher ID: B-3272-2017

Федеральное государственное бюджетное образовательное учреждение высшего образования «Алтайский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияAltai State Medical UniversityRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Министерства здравоохранения Российской ФедерацииРоссияBekhterev National Medical Research Center for Psychiatry and NeurologyRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Министерства здравоохранения Российской Федерации ; Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр им. В.А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияBekhterev National Medical Research Center for Psychiatry and Neurology; Almazov National Medical Research CentreRussian Federation202422102024163212–222Copyright © Romanov A.S., Sharakhova E.F., Shova N.I., Mikhailov V.A., 20242024Романов А.С., Шарахова Е.Ф., Шова Н.И., Михайлов В.А.Romanov A.S., Sharakhova E.F., Shova N.I., Mikhailov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/1102Background

Background. Epilepsy underdiagnosis in Russia, population aging, innovative drugs and expensive treatment regimens, the introduction of additional and alternative methods such as neurosurgery, annually increase the cost for treatment of epilepsy patients. In this regard, an issue of maximizing benefits for the largest number of the population becomes relevant. Pharmacoeconomical research within the assessment of healthcare technologies helps to choose the most economically and medically effective treatment strategy among numerous alternatives.

Objective

Objective: analysis of epilepsy-associated costs in the Russian Federation, aimed at supporting decision-making processes in the field of health policy and financing.

Material and methods

Material and methods. The empirical study was based on collecting the data on a continuous sampling of 384 epilepsy outpatient records from subjects aged 19 to 79 years for the period 2019–2022. The issues related to all costs of epilepsy were discussed. While planning, conducting and analyzing these studies, the principles of strengthening the reporting of observational studies in epidemiology (STROBE) were taken into account.

Results

Results. The total annual per-patient expenditure on epilepsy treatment comprised a fifth of gross domestic product per capita. Indirect costs exceed direct cost savings. It was found out that the economic damage caused to society, family, and individual related to epilepsy is three times higher than the direct costs.

Conclusion

Conclusion. The results obtained are consistent with other publications in which unemployment among epilepsy patients is one of the major cost-determining factors and illustrates a critical need to maintain employment for such patients or to find suitable alternative work through professional retraining.

Актуальность

Актуальность. Гиподиагностика эпилепсии в России, старение населения, инновационные препараты и дорогостоящие схемы лечения, внедрение дополнительных и альтернативных методов, таких как нейрохирургия, ежегодно увеличивают медицинские расходы на лечение пациентов с эпилепсией. Становится актуальным вопрос максимизации пользы для наибольшего числа граждан. Фармакоэкономические исследования как часть оценки технологий здравоохранения помогают из многочисленных альтернатив выбрать тактику лечения, наиболее эффективную с экономической и медицинской точек зрения.

Цель

Цель: анализ расходов, связанных с эпилепсией, в Российской Федерации, направленный на поддержку процессов принятия решений в области политики здравоохранения и финансирования.

Материал и методы

Материал и методы. Эмпирической базой исследования послужили данные копировки методом сплошной выборки

384 амбулаторных карт пациентов с эпилепсией возрастной категории от 19 до 79 лет за период 2019–2022 гг. Рассмотрена проблематика учета всех затрат на заболевание. При планировании, проведении и анализе данных исследований учитывали принципы повышения качества отчетов о наблюдательных исследованиях в эпидемиологии (англ. strenghtening the reporting of observational studies in epidemiology, STROBE).

Результаты

Результаты. Общие ежегодные траты на лечение эпилепсии в расчете на 1 пациента составили пятую часть от размера валового внутреннего продукта на душу населения. Непрямые затраты превосходят сумму прямых расходов. Установлено, что экономический ущерб, наносимый обществу, семье, индивидууму в связи с заболеванием, троекратно превышает прямые затраты.

Заключение

Заключение. Полученные результаты показывают, что безработица среди больных эпилепсией относится к основным факторам, определяющим затраты, и подтверждают критическую необходимость сохранения занятости таких пациентов или поиска подходящей альтернативной работы путем профессиональной переподготовки.

Эпилепсияпрямые затратыкосвенные затратыанализ стоимости болезниоценка технологий здравоохраненияEpilepsydirect costsindirect costscost-of-illness analysishealth technology assessmentReferencesDe Boer H.M. “Out of the shadows”: a global campaign against epilepsy. Epilepsia. 2002; 43 (6): 7–8. https://doi.org/10.1046/j.15281157.43.s.6.4.x.De Boer H.M. “Out of the shadows”: a global campaign against epilepsy. Epilepsia. 2002; 43 (6): 7–8. https://doi.org/10.1046/j.15281157.43.s.6.4.x.Романов А.С., Шарахова Е.Ф. Медико-социальные аспекты эпилепсии (обзор литературы). Современные проблемы здраво- охранения и медицинской статистики. 2023; 3: 80–103. https://doi.org/10.24412/2312-2935-2023-3-80-103.Romanov A.S., Sharakhova E.F. Medical and social aspects of epilepsy (literature review). Current Problems of Health Care and Medical Statistics. 2023; 3: 80–103 (in Russ.). https://doi.org/10.24412/2312-2935-2023-3-80-103.]Melkamu P., Animut Y., Minyihun A., et al. Cost of illness of epilepsy and associated factors in patients attending adult outpatient department of University of Gondar Referral Hospital, Northwest Ethiopia. Risk Manag Healthc Policy. 2021; 14: 2385–94. https://doi.org/10.2147/RMHP.S289113.Melkamu P., Animut Y., Minyihun A., et al. Cost of illness of epilepsy and associated factors in patients attending adult outpatient department of University of Gondar Referral Hospital, Northwest Ethiopia. Risk Manag Healthc Policy. 2021; 14: 2385–94. https://doi.org/10.2147/RMHP.S289113.Begley C., Wagner R.G., Abraham A., et al. The global cost of epilepsy: a systematic review and extrapolation. Epilepsia. 2022; 63 (4): 892– 903. https://doi.org/10.1111/epi.17165.Begley C., Wagner R.G., Abraham A., et al. The global cost of epilepsy: a systematic review and extrapolation. Epilepsia. 2022; 63 (4): 892– 903. https://doi.org/10.1111/epi.17165.Guekht A., Brodie M., Secco M., et al. The road to a World Health Organization global action plan on epilepsy and other neurological disorders. Epilepsia. 2021; 62 (5): 1057–63. https://doi.org/10.1111/epi.16856.Guekht A., Brodie M., Secco M., et al. The road to a World Health Organization global action plan on epilepsy and other neurological disorders. Epilepsia. 2021; 62 (5): 1057–63. https://doi.org/10.1111/epi.16856.Willems L.M., Hochbaum M., Zöllner J.P., et al. Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020. Epilepsia. 2022; 63 (6): 1591–602. https://doi.org/10.1111/epi.17229.Willems L.M., Hochbaum M., Zöllner J.P., et al. Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020. Epilepsia. 2022; 63 (6): 1591–602. https://doi.org/10.1111/epi.17229.Thomas S.V., Sarma P.S., Alexander M., et al. Economic burden of epilepsy in India. Epilepsia. 2001; 42 (8): 1052–60. https://doi.org/10.1046/j.1528-1157.2001.0420081052.x.Thomas S.V., Sarma P.S., Alexander M., et al. Economic burden of epilepsy in India. Epilepsia. 2001; 42 (8): 1052–60. https://doi.org/10.1046/j.1528-1157.2001.0420081052.x.Gao L., Xia L., Pan S.Q., et al. Burden of epilepsy: a prevalence- based cost of illness study of direct, indirect and intangible costs for epilepsy. Epilepsy Res. 2015; 110: 146–56. https://doi.org/10.1016/j.eplepsyres.2014.12.001.Gao L., Xia L., Pan S.Q., et al. Burden of epilepsy: a prevalence- based cost of illness study of direct, indirect and intangible costs for epilepsy. Epilepsy Res. 2015; 110: 146–56. https://doi.org/10.1016/j.eplepsyres.2014.12.001.García-Contreras F., Constantino-Casas P., Castro-Ríos A., et al. Direct medical costs for partial refractory epilepsy in Mexico, archives of medical research. 2006; 37 (3): 376–83. https://doi.org/10.1016/j.arcmed.2005.07.005.García-Contreras F., Constantino-Casas P., Castro-Ríos A., et al. Direct medical costs for partial refractory epilepsy in Mexico, archives of medical research. 2006; 37 (3): 376–83. https://doi.org/10.1016/j.arcmed.2005.07.005.Jędrzejczak J., Majkowska-Zwolińska B., Chudzicka-Bator A., et al. Economic and social cost of epilepsy in Poland: 5-year analysis. Eur J Health Econ. 2021; 22 (3): 485-97. https://doi.org/10.1007/s10198-021-01269-1.Jędrzejczak J., Majkowska-Zwolińska B., Chudzicka-Bator A., et al. Economic and social cost of epilepsy in Poland: 5-year analysis. Eur J Health Econ. 2021; 22 (3): 485-97. https://doi.org/10.1007/s10198-021-01269-1.Al-Zakwani I., Hanssens Y., Deleu D., et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure. 2003; 12 (8): 555–60. https://doi.org/10.1016/S1059-1311(03)00068-2.Al-Zakwani I., Hanssens Y., Deleu D., et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure. 2003; 12 (8): 555–60. https://doi.org/10.1016/S1059-1311(03)00068-2.Wibecan L., Fink G., Tshering L., et al. The economic burden of epilepsy in Bhutan. Trop Med Int Health. 2018; 23 (4): 342–58. https://doi.org/10.1111/tmi.13035.Wibecan L., Fink G., Tshering L., et al. The economic burden of epilepsy in Bhutan. Trop Med Int Health. 2018; 23 (4): 342–58. https:// doi.org/10.1111/tmi.13035.Willems L.M., Richter S., Watermann N., et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 – a ten-year overview. Epilepsy Behav. 2018; 9 (83): 28–35. https://doi.org/10.1016/j.yebeh.2018.03.025.Willems L.M., Richter S., Watermann N., et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 – a ten-year overview. Epilepsy Behav. 2018; 9 (83): 28–35. https://doi.org/10.1016/j.yebeh.2018.03.025.Pirker S., Graef A., Gachter M., Baumgartner C. Costs of epilepsy in Austria: unemployment as a primary driving factor. Seizure. 2021; 89: 24–9. https://doi.org/10.1016/j.seizure.2021.04.020.Pirker S., Graef A., Gachter M., Baumgartner C. Costs of epilepsy in Austria: unemployment as a primary driving factor. Seizure. 2021; 89: 24–9. https://doi.org/10.1016/j.seizure.2021.04.020.Wijnen B.F.M., Schat S.L., de Kinderen R.J.A., et al. Burden of disease of people with epilepsy during an optimized diagnostic trajectory: costs and quality of life. Epilepsy Res. 2018; 146: 87–93. https://doi.org/10.1016/j.eplepsyres.2018.07.024.Wijnen B.F.M., Schat S.L., de Kinderen R.J.A., et al. Burden of disease of people with epilepsy during an optimized diagnostic trajectory: costs and quality of life. Epilepsy Res. 2018; 146: 87–93. https://doi.org/10.1016/j.eplepsyres.2018.07.024.Незнанов Н.Г., Громов С.А., Михайлов В.А. и др. Эпилепсия, качество жизни, лечение. СПб.: Издательство ВМА; 2005: 294 c.Neznanov N.G., Gromov S.A., Mikhailov V.A., et al. Epilepsy, quality of life, treatment. Saint Petersburg: Izdate’stvo VMA; 2005: 294 pp. (in Russ.).]Романов А.С., Шарахова Е.Ф. Маркетинговые исследования национального рынка противоэпилептических препаратов. Journal of Siberian Medical Sciences. 2022; 6 (4): 48–60. https://doi.org/10.31549/2542-1174-2022-6-4-48-60.Romanov A.S., Sharakhova E.F. Marketing research on the national antiepileptic drug market in Russia. Journal of Siberian Medical Sciences. 2022; 6 (4): 48–60 (in Russ.). https://doi.org/10.31549/2542-1174-2022-6-4-48-60.]Ягудина Р.И., Серпик В.Г., Куликов А.Ю. Фармакоэкономика для организаторов здравоохранения. Алгоритм принятия решений на основе фармакоэкономической оценки. Фармакоэкономика: теория и практика. 2014; 2 (1): 13–20. https://doi.org/10.30809/phe.1.2014.47.Yagudina R.I., Serpik V.G., Kulikov A.Yu. Pharmacoeconomics for the health care managers: decision-making algorithm based on pharmacoeconomic assessments. Pharmacoeconomics: Theory and Practice. 2014; 2 (1): 13–20 (in Russ.). https://doi.org/10.30809/phe.1.2014.47.]Gao L., Hu H., Zhao F.L., Li S.C. Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples. PLoS One. 2016; 11 (1): e0147169. https://doi.org/10.1371/journal.pone.0147169.Gao L., Hu H., Zhao F.L., Li S.C. Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples. PLoS One. 2016; 11 (1): e0147169. https://doi.org/10.1371/journal.pone.0147169.Решетников А.В., Алексеева В.М., Галкин Е.Б. Экономика здравоохранения. М.: ГЭОТАР-Медиа; 2010: 272 с.Решетников А.В., Алексеева В.М., Галкин Е.Б. Экономика здравоохранения. М.: ГЭОТАР-Медиа; 2010: 272 с. [Reshetnikov A.V., Alekseeva V.M., Galkin E.B. Health economics. Мoscow: GEOTAR-Мedia; 2010: 272 pp. (in Russ.).]Ягудина Р.И., Серпик В.Г. Методология анализа затрат. Фармакоэкономика: теория и практика. 2016; 4 (2): 5–9. https://doi.org/10.30809/phe.2.2016.8.Yagudina R.I., Serpik V.G. Methodology of cost analysis. Pharmacoeconomics: Theory and Practice. 2016; 4 (2): 5–9 (in Russ.). https://doi.org/10.30809/phe.2.2016.8.]Tekin R., Sahin B. Comparison of top down and bottom up cost approaches in colon and rectal cancer treatment. Health. 2021; 13 (2): 90–109. https://doi.org/10.4236/health.2021.132009.Tekin R., Sahin B. Comparison of top down and bottom up cost approaches in colon and rectal cancer treatment. Health. 2021; 13 (2): 90–109. https://doi.org/10.4236/health.2021.132009.Guy W. (Ed.) ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976: 218–22. Available at: https://archive.org/details/ecdeuassessmentm1933guyw/page/218/mode/2up?view=theater (accessed 03.04.2024).Guy W. (Ed.) ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976: 218–22. Available at: https://archive.org/details/ecdeuassessmentm1933guyw/page/218/mode/2up?view=theater (accessed 03.04.2024).World Bank. The world by income. Available at: https://datatopics.worldbank.org/world-development-indicators/images/figures-png/world-by-income-sdg-atlas-2018.pdf (accessed 15.03.2024).World Bank. The world by income. Available at: https://datatopics.worldbank.org/world-development-indicators/images/figures-png/world-by-income-sdg-atlas-2018.pdf (accessed 15.03.2024).Willems L.M., Kondziela J.M., Knake S., et al. Counseling and social work for people with epilepsy in Germany: a cross-sectional multicenter study on demand, frequent content, patient satisfaction, and burden-of-disease. Epilepsy Behav. 2019; 92: 114–20. https://doi.org/10.1016/j.yebeh.2018.12.004.Willems L.M., Kondziela J.M., Knake S., et al. Counseling and social work for people with epilepsy in Germany: a cross-sectional multicenter study on demand, frequent content, patient satisfaction, and burden-of-disease. Epilepsy Behav. 2019; 92: 114–20. https:// doi.org/10.1016/j.yebeh.2018.12.004.Willems L.M., Reif P.S., Knake S., et al. Noncompliance of patients with driving restrictions due to uncontrolled epilepsy. Epilepsy Behav. 2019; 91: 86–9. https://doi.org/10.1016/j.yebeh.2018.04.008.Willems L.M., Reif P.S., Knake S., et al. Noncompliance of patients with driving restrictions due to uncontrolled epilepsy. Epilepsy Behav. 2019; 91: 86–9. https://doi.org/10.1016/j.yebeh.2018.04.008.

The authors declare that there are no conflicts of interest present.